Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Intravenous CTLA4-lg Treatment in Recent Onset Type 1 Diabetes Mellitus

This study has been completed.
Sponsor:
Collaborators:
Juvenile Diabetes Research Foundation
American Diabetes Association
Information provided by (Responsible Party):
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
ClinicalTrials.gov Identifier:
NCT00505375
First received: July 20, 2007
Last updated: December 17, 2013
Last verified: December 2013

July 20, 2007
December 17, 2013
February 2008
May 2012   (final data collection date for primary outcome measure)
Insulin production (C-peptide secretion) [ Time Frame: 2 years of follow up ] [ Designated as safety issue: No ]
Insulin production (C-peptide secretion)
Complete list of historical versions of study NCT00505375 on ClinicalTrials.gov Archive Site
  • HbA1c [ Time Frame: 2 years of follow up ] [ Designated as safety issue: No ]
  • Number and severity of hypoglycemic events [ Time Frame: 2 years of follow up ] [ Designated as safety issue: No ]
  • Immunologic outcomes [ Time Frame: 2 years of follow up ] [ Designated as safety issue: No ]
  • HbA1c
  • Insulin dose
  • Number and severity of hypoglycemic events
  • Immunologic outcomes
Not Provided
Not Provided
 
Intravenous CTLA4-lg Treatment in Recent Onset Type 1 Diabetes Mellitus
Effects of CTLA-4 Ig (Abatacept) On The Progression of Type 1 Diabetes In New Onset Subjects

The purpose of this study is to determine whether treatment with CTLA4-Ig (Abatacept) in individuals with new onset T1DM will improve insulin secretion (C-peptide production) compared to placebo.

Type 1 diabetes mellitus (T1DM) is a T-cell mediated autoimmune disease in which insulin-producing beta cells are completely or near completely destroyed resulting in life-long dependence on exogenous insulin.

CTLA4-Ig (Abatacept) inhibits a crucial stimulatory pathway in the activation of T cells. By this mechanism, the drug is thought to arrest or slow the T cell mediated autoimmune destruction of beta-cells and preserve their function. At the time of clinical onset of T1DM, a significant amount of insulin producing beta cells are destroyed, but as many as 10-20% are still capable of insulin production. By using CTLA4-Ig close to the onset of T1DM, we hope to arrest or slow down the autoimmune destruction of these beta-cells and extend the endogenous insulin production. CTLA4-Ig regulates T cell function but does not deplete T cells. Therefore, its safety profile appears to be better than other immunosuppressive agents.

Eligible participants will be randomized to the experimental or control groups. The experimental group will receive intravenous infusions of CTLA-4 Ig. The first infusion will occur at the time of randomization, followed by another infusion 2 and 4 weeks later. Subsequent infusions will be given monthly for two years during the treatment phase of the study. There is a total of 27 infusions during the treatment phase of the study.

Participants in the control group will receive intravenous infusions of placebo according to the same schedule outlined above.

Both groups will receive standard intensive diabetes treatment with insulin and dietary management.

All participants randomized into the study will be seen at study site monthly for 24 months and then every 6 months for up to an additional 2 years. Participants will undergo assessments of their insulin production, immunologic status, overall health and well being and diabetes care.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Type 1 Diabetes Mellitus
  • Drug: CTLA-4 Ig
    Intravenous infusion of 10 mg/kg of CTLA-4 Ig every other week for the first two doses and then every 28 days for a total of 27 doses
    Other Name: Abatacept
  • Other: Placebo
    Intravenous infusions of placebo every other week for the first two doses and then every 28 days for a total of 27 doses
  • Experimental: 1
    Intravenous infusions of CTLA-4 Ig
    Intervention: Drug: CTLA-4 Ig
  • Placebo Comparator: 2
    Intravenous infusions of placebo
    Intervention: Other: Placebo

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
112
May 2012
May 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Age 6-45
  2. Within 3 months (100 days) of diagnosis of T1DM based on ADA criteria
  3. At least one diabetes-related autoantibody
  4. Stimulated C-peptide level >0.2 pmol/ml by MMTT conducted 21 days after diagnosis of T1DM and within 37 days of randomization
  5. At least three months from last live immunization received and willing to forgo live vaccinations for three months following last dose of study treatment

Exclusion Criteria:

  1. Immunodeficiency, chronic lymphopenia, active infection, positive PPD result or a history of malignancy
  2. Serologic evidence of current or past HIV, Hepatitis B or C
  3. Pregnancy, lactation, or intention of pregnancy while on study
  4. Current use of immunosuppressive agents, or medications known to influence glucose tolerance or glycemic control
  5. Current participation in another T1DM treatment study
Both
6 Years to 45 Years
No
Contact information is only displayed when the study is recruiting subjects
United States,   Canada
 
NCT00505375
CTLA (IND)
Yes
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
  • National Institute of Allergy and Infectious Diseases (NIAID)
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
  • Juvenile Diabetes Research Foundation
  • American Diabetes Association
Principal Investigator: Tihamer Orban, MD Joslin Diabetes Center
Study Chair: Jay Skyler, MD University of Miami
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
December 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP